Register Login

Recombinant ADAMTS13 Therapeutic

On November 9, 2023, Takeda’s recombinant ADAMTS13 received FDA approval for the care of congenital thrombotic thrombocytopenic purpura [cTTP]. Click here for their news release. Click here for the US Thrombotic Microangiopathy Alliance for more cTTP information and information on the family of TMAs.

Comments (0)
Bleeding Disorders

No comments here.

Leave a Reply